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Purpose
The purpose of this study is to compare the treatment outcomes for locally advanced 
resectable hypopharyngeal cancer between organ-preserving chemoradiotherapy (CRT) and
surgery followed by radiotherapy (SRT).
Materials and Methods
We reviewed 91 patients with stage III/IV hypopharyngeal squamous cell carcinoma treated
with radiotherapy (RT). In the CRT group (n=34), 18 patients were treated with concurrent
CRT and 16 patients with induction chemotherapy plus concurrent CRT. In the SRT group
(n=57), six patients were treated with total laryngopharyngectomy, 34 patients with total 
laryngectomy (TL) and partial pharyngectomy (PP), and 17 patients with PP, which were 
followed by adjuvant radiotherapy (n=41) or CRT (n=16). The median RT dose was 70 Gy
for CRT and 59.4 Gy for SRT.
Results
Five-year local control (84.1% vs. 90.9%), and disease-free survival (DFS, 51.0% vs. 52.7%)
and overall survival (OS, 58.6% vs. 56.6%) showed no significant difference between the
CRT and SRT groups. The functional larynx-preservation rate was higher in the CRT group
(88.2% vs. 29.8%). Treatment-related toxicity, requiring surgical intervention, occurred more
frequently in the SRT group (37% vs. 12%). In the SRT group, TL resulted in a significantly
higher DFS than larynx-sparing surgery (63.9% vs. 26.5%, p=0.027). Treatment outcome
of the SRT group improved when only patients with TL were considered (n=40); however, 
5-year OS (67.1% vs. 58.6%, p=0.830) and DFS (63.9% vs. 51.0%, p=0.490) did not 
improve significantly when compared to the CRT group.
Conclusion
Organ preserving CRT provided a treatment outcome that is comparable to SRT for locally
advanced hypopharyngeal cancer, while offering an opportunity for functional larynx-preser-
vation and reduced treatment-related toxicity.
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Introduction
Squamous cell carcinoma (SCC) of the hypopharynx is
rare, consisting of 3%-5% of all head and neck SCC cases [1].
Hypopharynx is characterized with thin mucosal lining 
(< 1 cm) providing minimal barrier with propensity to sub-
mucosal spread. A rich lymphatic network of hypopharynx 
results in frequent lymph node metastases: ipsilateral nodal
metastasis in 60%-80% and contralateral occult nodal metas-
tasis in up to 40% [2] of patients at the time of diagnosis.
Stage III or IV in 70%-85% patients are reported in large 
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series, and 5-year survival is only 15%-45% [3].
The preservation of speech and swallowing function in the
treatment of laryngeal and hypopharyngeal cancer is impor-
tant. In early-stage disease, both surgery and radiotherapy
(RT) are treatment options that preserve the organ and func-
tion [3,4]. For locally advanced hypopharyngeal cancer, 
traditional approach was laryngopharyngectomy and pha-
ryngeal reconstruction with or without adjuvant RT, result-
ing in a loss of natural voice production. Addition of chem-
otherapy to RT alone in advanced cancer improved the out-
come compared to surgery plus RT, while allowing larynx
preservation [5]. However, no clear guidelines specific to 
hypopharyngeal cancer are available. Most evidences on 
laryngeal preservation are from laryngeal cancer or mixed
head and neck cancer studies. A few studies reported treat-
ment results dedicated to hypopharyngeal cancer, albeit of
mixed population, including early stage cancers and 
advanced unresectable cancers [6].
We reviewed the treatment outcome of locally advanced
resectable SCC of the hypopharynx, with comparative analy-
sis between organ-preserving chemoradiotherapy (CRT) and
radical surgery followed by adjuvant RT.
Materials and Methods
1. Patients
A total of 136 consecutive patients, who received definitive
or adjuvant RT for stage III or IV SCC of the hypopharynx
between January 2002 and June 2012, were reviewed. All 
patients underwent pretreatment evaluation, including a
complete history and physical examination, head and neck
examination with laryngoscopy, and computed tomography
(CT) and magnetic resonance imaging of the head and neck
region. All patients were staged in accordance to the 2010
American Joint Committee on Cancer (AJCC) TNM staging
system (seventh edition). Patients treated with definitive RT
were staged clinically, while both clinical and pathologic
stages were reported in postoperative cases. Patients having
T1N1 disease (n=3), distant metastasis (n=3), double primary
tumor (n=11), unresectable disease or compromised speech
or swallowing functions at presentation (n=4), treated with
RT alone (n=2), incomplete RT (n=3), re-irradiation (n=2),
and treated with trans-oral robotic surgery (n=17) were 
excluded, leaving 91 patients for analysis. The study protocol
conforms to the Declaration of Helsinki of 1975 as revised in
1983 and was approved by our Institutional Review Board.
2. Treatment
Among 91 patients, 57 patients were treated with upfront
surgery followed by adjuvant RT (SRT group), and 34 
patients were treated with definitive chemoradiotherapy
(CRT group). Decisions to undergo CRT were based upon
age, medical co-morbidities, and patients’ preferences. The
SRT group included radical surgery followed by RT (n=41)
or concurrent CRT (n=16). Types of surgery included total
laryngopharyngectomy (n=6), total laryngectomy (TL) and
partial pharyngectomy (PP) (n=34), and partial laryngectomy
with PP (n=17). The CRT group included patients treated
with concurrent CRT (n=18) and induction chemotherapy,
followed by concurrent CRT (n=16). Concurrent chemother-
apy regimens included weekly DDP (cisplatin 40 mg/m2),
weekly FP (5-fluorouracil [5-FU] 750 mg/m2, cisplatin 20
mg/m2), and TPF (5-FU 750 mg/m2, taxotere 70 mg/m2, 
cisplatin 75 mg/m2) every 3 weeks. Induction chemotherapy
regimen consisted of FP every 3 weeks for 3 cycles, or TPF
every 3 weeks for 2 cycles. All patients underwent CT-based
RT planning with either 3-dimensional conformal RT or 
intensity-modulated radiotherapy (IMRT). The median RT
dose was 59.4 Gy (range, 50.4 to 70.2 Gy) for the SRT group
and 70 Gy (range, 59.4 to 72 Gy) for the CRT group. For the
SRT group, neck dissection was performed for both sides of
the neck. Radical neck dissection or modified neck dissection
was performed for the involved neck and lateral neck dissec-
tion (selective neck dissection in 2 patients) for the clinically
uninvolved neck. For the CRT group, both sides of the neck
were included in the RT field. Grossly involved lymph nodes
were treated with 66-70 Gy, involved cervical nodal stations
with 60-63 Gy, and uninvolved nodal stations with 50-54 Gy.
Treatment-related toxicities were reported in accordance to
the Common Terminology Criteria for Adverse Events
(CTCAE) ver. 3.0. CTCAE grade 4 voice alterations or dys-
phagia after treatment was considered loss of laryngeal func-
tion.
3. Statistical analysis
The two groups were compared by a chi-square test to 
detect the differences in proportion. Survival was calculated
from the start of treatment until death or to the most recent
follow-up date. Survival curves were plotted using a Kaplan-
Meier method. Survival curves were compared using a log-
rank test for a univariate analysis. The Cox proportional
hazards model was used to assess independent predictors
for survival. A p-value of less than 0.05 was regarded as sta-
tistically significant.
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Results
1. Patient characteristics
Table 1 shows patient and tumor characteristics. The 
median age was 64 years (range, 36 to 80 years), and male
were predominant (94.5%). Pyriform sinus (80.2%) was the
most common subsite of the hypopharyngeal cancer, 
followed by pharyngeal wall (14.3%) and post-cricoid area
(5.5%). Fifty-seven patients (62.7%) had T3-T4a tumors and
65 patients (71.4%) had N2-3 nodal disease. Early disease not
requiring total laryngectomy (T1-2N0, T1N1) and unre-
sectable primary tumor (T4b) were excluded in this study.
2. Survival and prognostic factors
With the median follow-up of 50 months (range, 5 to 141
months), 5-year estimated local failure-free survival (LFFS),
locoregional failure-free survival (LRFFS), distant metasta-
sis-free survival (DMFS), disease-free survival (DFS), and
overall survival (OS) of all patients (n=91) were 88.3%, 76.9%,
83.3%, 52.1%, and 57.4%, respectively. In a univariate analy-
sis, age ! 60 years (vs. > 60) showed a significant correlation
with improved OS (p=0.049) while sex, subsite, stage, treat-
ment group, and RT modality showed no significant corre-
lation. Age ! 60 also showed a trend towards improved DFS
(p=0.076) (Table 2). 
3. Outcome comparison by treatment groups
Clinical features, including subsite, T stage, N stage, and
overall stage, were well balanced between the two treatment
groups, except for the proportion of female patients (1.8% vs.
11.8%, p=0.043) and use of IMRT (10.5% vs. 35.3%, p=0.004)
(Table 1). Five-year DFS (52.7% vs. 51.0%, p=0.991) and OS
(56.6% vs. 58.6%, p=0.713) showed no significant difference
between the SRT and CRT groups (Fig. 1A and B). LFFS
(90.9% vs. 84.1%, p=0.677), LRFFS (78.8% vs. 73.7%, p=0.893),
and DMFS (80.5% vs. 88.0%, p=0.507) also showed no signif-
icant differences.
During the follow-up, treatment failure occurred in 21 
patients (36.8%) in the SRT group and 12 patients in the CRT
group (35.3%). The first sites of failure were three local, five
regional, three locoregional, eight distant, one local and 
distant, and one regional and distant in the SRT group, and
five local, three regional, and four distant in the CRT group.
Within the SRT group, one local, two locoregional, four 
regional, and four distant failures occurred among the 40 
patients who received total laryngectomy (27.5% failure),
Table 1. Patient characteristics
Characteristic Total (n=91) SRT (n=57) CRT (n=34) p-value
Median age (range, yr) 64 (36-80) 64 (39-81) 65.5 (37-81)
Sex Male 86 (94.5) 56 (98.2) 30 (88.2) 0.043
Female 5 (5.5) 1 (1.8) 4 (11.8)
Subsite PS 73 (80.2) 48 (84.2) 25 (73.5) 0.401
PW 13 (14.3) 6 (10.5) 7 (20.6)
PC 5 (5.5) 3 (5.3) 2 (5.9)
cT stage cT1 8 (8.8) 6 (10.5) 2 (5.9) 0.342
cT2 26 (28.6) 17 (29.8) 9 (26.5)
cT3 27 (29.7) 19 (33.3) 8 (23.5)
cT4a 30 (33.0) 15 (26.3) 15 (44.1)
cN stage cN0 12 (13.2) 6 (10.5) 6 (17.6) 0.618
cN1 14 (15.4) 8 (14.0) 6 (17.6)
cN2 60 (65.9) 39 (68.4) 21 (61.8)
cN3 5 (5.5) 4 (7.0) 1 (2.9)
Stage III 17 (18.7) 11 (19.3) 6 (17.6) 0.629
IV a 68 (74.7) 42 (73.7) 27 (79.4)
IV b 6 (6.6) 4 (7.0) 1 (2.9)
RT 3DCRT 73 (80.2) 51 (89.5) 22 (64.7) 0.004
IMRT 18 (19.8) 6 (10.5) 12 (35.3)
Values are presented as number (%) unless otherwise indicated. SRT, surgery plus radiotherapy; CRT, chemoradiotherapy;
PS, pyriform sinus; PW, pharyngeal wall; PC, postcricoid; cT, clinical T stage; 3DCRT, 3D conformal radiotherapy; IMRT, 
intensity-modulated radiotherapy.
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and two local, one locoregional, one regional, one local and
distant, one regional and distant, four distant failures 
occurred among the 17 patients who received larynx-sparing
surgery (58.8% failure). Five-year DFS was significantly
higher after total laryngectomy than after larynx-sparing 
surgery (63.9% vs. 26.5%, p=0.027), while total laryngectomy
showed a trend towards improved OS compared with 
larynx-preservation surgery (67.1% vs. 31.8%, p=0.094) 
(Fig. 1C and D).
For a subgroup analysis, patients who received total laryn-
gectomy were selected from the SRT group (the SRT/TL
group, n=40) and their treatment outcome was compared
with the outcome of the CRT group (n=34). Survival param-
eters for the SRT/TL group improved when patients who 
received larynx-sparing surgery were excluded from the sub-
group analysis. However, no significant difference was seen
in 5-year DFS (63.9% vs. 51.0%, p=0.490), OS (67.1% vs.
58.6%, p=0.830), LFFS (90.9% vs. 84.1%, p=0.677), LRFFS
(83.1% vs. 73.7%, p=0.467), and DMFS (89.7% vs. 88.0%,
p=0.732) between the SRT/TL and CRT groups. 
4. Outcome of salvage treatment
Table 3 shows the outcome of salvage treatment among 
patients who had experienced local and/or regional failures.
Among the 13 patients in the SRT group, only two patients
received surgical resection of the recurrent primary tumor or
neck nodes, and eight patients were salvaged with chemo-
therapy or re-irradiation. All patients died of disease pro-
gression (survival after recurrence, 1 to 10 months) except for
the two patients who were salvaged successfully through 
re-irradiation with chemotherapy and neck dissection (sur-
vival after recurrence, 7 to 24 months). Among eight failures
in the CRT group, seven patients were salvaged with dissec-
tion of the primary tumor or recurrent cervical lymph nodes.
Among the seven patients treated with surgery, three were
alive without disease at the time of analysis (survival after
recurrence, 5 to 48 months) and three died of intercurrent
death without evidence of recurrence (survival after recur-
rence, 4 to 23 months). 
DFS, disease-free survival; OS, overall survival; CI, confidence interval; PS, pyriform sinus; PW, pharyngeal wall; PC, post-
cricoid; SRT, surgery plus radiotherapy; CRT, chemoradiotherapy; RT, radiotherapy; IMRT, intensity modulated radiotherapy;
3DCRT, 3 dimensional conformal radiotherapy.
Table 2. Univariate analysis for DFS and OS
Variable No. of patients (%) DFS OS
5-Yr DFS (%) 95% CI p-value 5-Yr OS (%) 95% CI p-value
Age (yr)
! 60 36 (40) 56.9 40.2-73.6 0.076 62.7 46.4-79.0 0.049
> 60 55 (60) 49.1 35.4-62.8 54.2 40.5-67.9
Sex
Female 5 (6) 80.0 44.9-115.1 0.396 75.0 32.5-117.5 0.260
Male 86 (94) 50.3 39.3-61.3 55.0 44.0-66.0
Subsite
PS 73 (80) 54.5 42.7-66.3 0.606 60.2 48.6-71.8 0.887
PW/PC 18 (20) 42.9 19.2-66.6 46.2 21.5-70.9
T stage
T1-2 34 (37) 57.8 40.7-74.9 0.539 60.0 42.9-77.1 0.641
T3-4 57 (63) 48.8 35.3-62.3 56.2 42.7-69.7
N stage
N0-1 26 (29) 52.6 33.0-72.2 0.652 59.3 39.5-79.1 0.517
N2-3 65 (71) 51.9 39.2-64.6 56.6 44.1-69.1
Treatment
SRT 57 (63) 52.7 39.4-66.0 0.991 56.6 43.5-69.7 0.713  
CRT 34 (37) 51.0 33.4-68.6 58.6 41.0-76.2
RT
IMRT 18 (20) 35.7 12.2-59.2 0.116 53.6 27.1-80.0 0.873
3DCRT 73 (80) 56.3 44.5-68.1 57.9 46.3-69.5
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5. Toxicity and laryngeal-function preservation rate
Treatment-related toxicities requiring surgical intervention
are listed in Table 4. Wound infection and flap failure are 
immediate surgical complications, while esophagopharyn-
geal stenosis, mucocutaneous fistula, and stoma stenosis are
late complications. Treatment-related toxicities were more
common in the SRT group (37% vs. 12%). Table 5 shows 
toxicities in accordance to CTCAE ver. 3.0 after combined
treatment, and grade 4 in voice alteration or dysphagia was 
considered loss of laryngeal function. Among the 57 patients
in the SRT group, 17 retained functional larynx by avoiding
total laryngectomy, allowing laryngeal function preservation
rate of 29.8%. Among the 34 patients in the CRT group, 30
patients retained a functional larynx (88.2%). Loss of laryn-
geal function in four patients in the CRT group was due to
local recurrence: three patients after total laryngectomy and
one patient from wound infection after salvage partial laryn-
gectomy.
Discussion
Selecting the optimal treatment strategy for locally 
advanced hypopharyngeal cancer needs to take into account
the extent of the tumor, status of laryngeal function, and 
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Fig. 1. Comparison of 5-year disease-free survival (A) and 5-year overall survival (B) between the surgery followed by 
radiotherapy (SRT) and chemoradiotherapy (CRT) groups; comparison of 5-year disease-free survival (C) and 5-year overall
survival (D) between total laryngectomy and larynx-sparing surgery in the SRT group.
patients’ desire for voice preservation. Early stage hypopha-
ryngeal cancer amenable to larynx preservation (most T1N0
and selected T2N0 tumors) may be treated by definitive RT
alone or partial laryngopharyngectomy [3,4]. Concurrent
CRT or induction chemotherapy, followed by CRT, is recom-
mended for T4b or unresectable tumors [7]. It is the spectrum
of disease that fall between these early and very advanced
disease groups, namely locally advanced resectable hypo-
pharyngeal cancer, that have several treatment options with
no clear advantage of one treatment modality over another. 
The current study makes a comparison between larynx
preserving CRT and radical surgery followed by adjuvant
RT, which are both feasible options for locally advanced 
resectable hypopharyngeal cancer. The 5-year DFS and OS
of 52.1% and 57.4% for all patients were higher than or at
least comparable to the results from previous studies [1,5,8].
In this study, the two treatment groups showed comparable
DFS and OS. All patients in SRT group underwent adjuvant
RT of median 60 Gy with or without concurrent chemother-
apy. It is a well-known fact that postoperative RT or CRT 
improves tumor control in head and neck cancer patients
with high risk features [9]. However, the cost of using adju-
vant RT or CRT to improve disease control and survival may
be substantial, namely increased treatment-related toxicities
and prolongation of the total treatment time. Both treatment
groups in the current study were subjected to RT; however,
it is difficult to compare treatment-related complications 
attributable exclusively to RT, since all of the patients 
received multi-modality treatment. On the other hand, the
SRT group experienced higher incidence of surgery-related
complications, including wound infection, flap failure, steno-
sis, and fistula, while patients in the CRT group experienced
such complications only when patients were subjected to 
salvage surgery after a local/regional failure (Table 4).
Another treatment-related complication, which is often
overlooked, is a reduced rate of successful salvage treatment
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Table 3. Failure pattern and outcome of salvage treatment
Survival 
Patient Age (yr) Subsite Stage Treatment Failure Stage at Salvage Salvage Current afterNo. /Sex pattern failure treatment response status recurrence 
(mo)
1 70/M PS pT1N2c P/P+RT R & D N2cM1 CTx PD DOD 1
2 63/M PW pT2N2c P/P+RT R N1 (CA invas) None n/a DOD 9
3 50/M PS pT4aN0 P/P+RT L T4aN0 Excision PD DOD 10
4 65/M PW pT2N2b P/P+RT L & R T3N1 None (conservative) n/a DOD 2
5 73/M PW pT3N1 P/P+RT L & D T4aN0M1 CTx PD DOD 4
6 54/M PW pT2N2b P/P+RT L T3N0 CCRT CR AWOD 24
7 55/M PS pT4aN2c T/L+CCRT R N1 None (refused) n/a DOD 4
8 47/M PS pT4aN2c T/L+RT R N2b CCRT PD DOD 10
9 65/M PS pT4aN3 T/L+CCRT L & R T4aN2b CTx PD DOD 4
10 63/M PS pT4aN2b T/L+RT R N2c CTx PD DOD 7
11 72/M PS pT2N1 T/L+CCRT L & R T4aN2c CCRT PD DOD 4
12 54/M PS pT4aN1 T/L+RT R N2c Neck dissection NED AWOD 7
13 57/M PS pT4aN2b T/L+CCRT L T4aN0 CTx PD DOD 5
14 66/M PS cT3N0 Induction+CCRT L T4a None n/a DOD 0
15 66/M PS cT4aN2b Induction+CCRT R N2b Neck dissection PD DOD 9
16 77/M PS cT4aN2b Induction+CCRT L T4N0 Transoral P/P NED DOOC 4
17 63/M PS cT1N2b Induction+CCRT R N1 (CA invas) Neck dissection NED DOOC 17
18 40/M PC cT4aN0 CCRT L T4a TLP NED DOOC 23
19 68/M PS cT3N1 CCRT L T4aN0 TL/PP NED AWOD 48
20 66/M PS cT4aN0 CCRT L T4aN0 TL/PP NED AWOD 45
21 57/F PC cT2N2c CCRT R N2b Neck dissection NED AWOD 5
PS, pyriform sinus; P/P, partial pharyngectomy; RT, radiotherpy; R, regional; D, distant; CTx, chemotherapy; PD, progression
of disease; DOD, died of disease; PW, pharyngeal wall; CA, carotid artery; n/a, not available; L, local; CCRT, concurrent
chemoradiotherapy; CR, complete remission; AWOD, alive without disease; T/L, total laryngectomy; NED, no evidence of
disease; TLP, total laryngopharyngectomy; DOOC, died of other cause; PC, postcricoid; TL/PP, total laryngectomy & partial
pharyngectomy.
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in case of treatment failure. In Fig. 1A and B, DFS curve for
SRT is slightly higher than that of CRT, while OS curve for
CRT is higher than that of SRT, especially through the later
period of follow-up. Such reversal may have been caused by
increased number of treatment-related toxicities, higher rate
of unsuccessful salvage, or higher incidence of deaths unre-
lated to disease progression or toxicity during follow-up in
the SRT group. Analysis of treatment outcome after 
local and/or regional failure suggests that CRT allowed
more effective salvage treatment in comparison with SRT
(Table 3). In the CRT group, six out of eight patients were
salvaged through dissection of the primary tumor or recur-
rent cervical lymph nodes: salvage efforts were successful
with three of these patients still alive without disease and
three patients died of intercurrent death without evidence of
recurrence. Outcome of salvage treatment in the SRT group
was less than favorable. Eight of the 13 patients were treated
with chemotherapy or re-irradiation, three patients did not
receive any treatment, and only two patients received surgi-
cal resection of the recurrent tumor. All patients died of dis-
ease progression, except for the two patients who were
salvaged successfully with re-irradiation and neck dissection.
In a clinical setting, most patients who are treated with sur-
gery for stage III/IV hypopharyngeal cancer also receive 
adjuvant RT or CRT. Options for salvage treatment after such
intensive combined treatment are limited. These patients
have already received radical resection of the primary tumor
and/or ipsilateral or bilateral neck dissection, followed by
radiation of 60 Gy or higher, which delivers maximum tol-
erable dose to the critical organs, such as pharyngeal swal-
lowing muscles, spinal cord, and parotid glands. Salvage
surgery or re-irradiation is extremely difficult, and chemo-
therapy alone, a remaining option, is often ineffective against
gross recurrent tumor. On the other hand, definitive chem-
oradiotherapy showed disease control and survival that are
comparable to the outcome of surgery plus adjuvant RT or
CRT, and in the case of a treatment failure, salvage surgery
often results in sustained disease control [5]. In a retrospec-
tive series, salvage surgery for failure after chemoradiother-
apy has shown acceptable oncologic outcome with no local
recurrence after salvage surgery [10].
There are concerns for increased toxicity from intensive
chemoradiotherapy, such as impairment of pharyngeal swal-
lowing muscles. Radiation dose to hypopharynx was associ-
ated with severe late toxicity in accordance to Radiation
Therapy Oncology Group (RTOG) analysis [11], and func-
tional outcome of CRT for head and neck cancer was not so
promising, despite improved locoregional control [12]. In 
unsuccessful organ preservation attempts, failures in func-
tion preservation may result from either toxicity from aggres-
sive CRT, extensive tumor infiltration into the organ at the
time of diagnosis, or from progression of disease. Patients
with functional impairment due to tumor infiltration should
be excluded from organ preservation candidates. In this
study, patients who had resectable tumor (< T4b) and intact
laryngeal function were included for analysis, and outcome
of larynx preserving CRT was compared to the outcome of
radical surgery followed by adjuvant RT/CRT. The function
preservation rate of 88.2% in the CRT group with loss of 
laryngeal function only due to local recurrence or complica-
tion of salvage surgery may lead to decisions favoring larynx
preserving treatment options.
Previous studies on treatment outcome of head and neck
cancer fail to take into account recent advances in treatment
modalities and discovery of new prognostic factors. The use
of IMRT allowed for a reduction of radiation-induced toxic-
ity, improved local and regional control, and potential for
improved survival in hypopharyngeal and other head and
neck cancer patients [13]. The most important factors that
contribute to morbidity in head and neck cancer patients 
undergoing intensive CRT are increased risk of dysphagia
and aspiration. By more accurate delineation of target 
volumes and sparing of pharyngeal constrictors and supra-
glottic larynx, patients treated with IMRT experienced fewer
swallowing problems than those treated with conventional
Table 4. Complications requiring surgical intervention
Values are presented as number (%). SRT, surgery plus 
radiotherapy; CRT, chemoradiotherapy.
Variable SRT (n=57) CRT (n=34)
Wound infection 4 (7) 1 (3)
Flap failure 4 (7) 0 (
Esophageal/pharyngeal stenosis 8 (14) 2 (6)
Pharyngocutaneous fistula 1 (2) 0 (
Stoma stenosis 4 (7) 1 (3)
Table 5. Laryngeal function after treatment
CTCAE, Common Terminology Criteria for Adverse
Events; SRT, surgery plus radiotherapy; CRT, chemoradio-
therapy. a)Numbers in parenthesis are due to total laryn-
gectomy or salvage surgery.
Variable CTCAE grade SRT (n=57) CRT (n=34)
Voice alteration 2 3 ( 1 (
3 1 ( 1 (
4 40 (40)a) 3 (3)a)
Dysphagia 2 35 (33)a) 7 (
3 9 (7) 4 (
4 0 ( 1 (1)a)
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RT [14]. Treatment deintensification in patients with human
papillomavirus (HPV) positive oropharyngeal cancer is gain-
ing interests [15]. A number of studies reported implication
of HPV-positive hypopharyngeal cancer in organ preserva-
tion therapy [16,17]. Further investigations may allow dein-
tensification in HPV-positive hypopharyngeal cancer and
reduction of treatment-related toxicities while maintaining
treatment outcome.
Efforts have been made to employ less than radical surgery
for hypopharyngeal cancer. Partial pharyngectomy and even
trans-oral resection of the tumor have been attempted with
the purpose of organ preservation [3,18]. However, these
limited surgery options should be explored with caution, 
especially in locally advanced cancer of the hypopharynx. In
this study, the outcome of patients treated with partial laryn-
gectomy and pharyngectomy was poor compared to the out-
come of total laryngectomy. Close and positive resection
margin was reported in six (35.3%) and five (29.4%) of the 17
patients who received larynx-sparing surgery and 11 (27.5%)
and six (15%) of 40 patients who received total laryngectomy.
Local failure occurred in three patients among the 40 who 
received total laryngectomy (7.5%) and in four among the 17
patients who received less than total laryngectomy (23.5%)
(Table 3). Larynx preservation through avoidance of total 
laryngectomy does not seem to be effective due to its high
rate of local failure. The incidence of submucosal extension
is up to 58% [19], and pathological studies showed that 
extent of submucosal involvement measured from the edge
of the tumor ranged 10-20 mm superiorly and 10-30 mm 
inferiorly [20,21], requiring resections margins of 3 cm infe-
riorly and 2 cm both superiorly and laterally. In locally 
advanced hypopharyngeal cancer, it is difficult to perform
laryngeal preservation surgery while achieving adequate 
resection margins.
One of the limitations in the current study is the inclusion
of a heterogeneous group of patients in the CRT group. The
CRT group consists of patients treated with concurrent CRT
as well as sequential CRT (induction chemotherapy plus RT
or CRT). Recent reports on the induction chemotherapy for
laryngeal preservation have shown equivalent outcome 
between sequential CRT and concurrent CRT [22,23]. The
number of cases reviewed in the current study is relatively
small, albeit only locally advanced resectable hypopharyn-
geal cancer cases are included for analysis. Disease charac-
teristics of SCC of the hypopharynx are unique, and
optimizing combined modality treatment needs to be 
explored further with a larger cohort of patients. In the 
current study, patient characteristics were well balanced 
between the SRT and CRT groups except for the proportion
of female patients, and the use of IMRT were higher in the
CRT group. In a univariate analysis, female sex and use of
IMRT did not result in significant improvement in DFS and
OS (Table 1). Although women have been found to achieve
somewhat improved outcomes compared to men, this may
in part be due to earlier-stage disease at diagnosis [24]. More-
over, the proportion of female patients (5.5%) was too small
to cause a significant difference in the treatment outcome in
this study. IMRT is superior over conventional RT in reduc-
ing radiation induced toxicities; however, its advantage in
patient survival is unclear. In a randomized trial comparing
IMRT and conventional RT for the treatment of oropharyn-
geal and hypopharyngeal SCC, IMRT was superior in 
preventing xerostomia; however, no significant differences
were observed in non-xerostomia late toxicities, locoregional
control or overall survival between IMRT and conventional
RT [25].
Conclusion
Organ preservation is not to be confused with function
preservation. For hypopharyngeal cancer, functions include
voice and swallowing, as well as quality of life. In hypopha-
ryngeal cancer with impaired laryngeal function at presen-
tation, laryngopharyngectomy with pharyngeal reconstruc-
tion is a preferred option permeating aspiration-free deglu-
tition and prosthetic voice instead of leaving intact but func-
tionless larynx. However, definitive CRT may be preferred
in locally advanced resectable hypopharyngeal cancer with
intact laryngeal function, providing treatment outcome com-
parable to surgery plus RT or CRT, while shortening total
treatment time and proving a salvage chance in the case of
local/regional failure.
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